Bist Ganesh, Park Seojeong, Song Chanju, Thapa Magar Til Bahadur, Shrestha Aarajana, Kwon Youngjoo, Lee Eung-Seok
College of Pharmacy, Yeungnam University, Gyeongsan 712-749, Republic of Korea.
College of Pharmacy, Graduate School of Pharmaceutical Sciences, Ewha Global Top5 program, Ewha Womans University, Seoul 120-750, Republic of Korea.
Eur J Med Chem. 2017 Jun 16;133:69-84. doi: 10.1016/j.ejmech.2017.03.048. Epub 2017 Mar 27.
With the aim to develop novel antiproliferative agents, a new series of eighteen dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines were systematically designed, prepared, and investigated for their topoisomerase (topo) I and IIα inhibitory properties and antiproliferative effect in three different human cancer cell lines (HCT15, T47D, and HeLa). Compounds 22-30 which possess a meta- or para-phenol on 2-, or 6-position of central pyridine ring showed significant dual topo I and topo IIα inhibitory activities with strong antiproliferative activities against all the tested human cancer cell lines. However, compounds 13-21 which possess an ortho-phenol on 2-, or 6-position of central pyridine ring did not show significant topo I and topo IIα inhibitory activities but displayed moderate antiproliferative activities against all the tested human cancer cell lines. Compound 23 exhibited the highest antiproliferative potency as much as 348.5 and 105 times compared to etoposide and camptothecin, respectively, in T47D cancer cell line. The structure-activity relationship study revealed that the para position of a hydroxyl group at 2-and 6-phenyl ring and chlorine atom at the para position of 4-phenyl ring of the central pyridine exhibited the most significant topo I and topo IIα inhibition, which might indicate introduction of the chlorine atom at the phenyl ring of 4-pyridine have an important role as dual inhibitors of topo I and topo IIα. Compound 30 which showed the most potent dual topo I and topo IIα inhibition with strong antiproliferative activity in T47D cell line was selected to perform further study on the mechanism of action, which revealed that compound 30 functions as a potent DNA non-intercalative catalytic topo I and IIα dual inhibitor.
为了开发新型抗增殖剂,系统设计、制备了一系列包含18个二羟基化的2,6-二苯基-4-氯苯基吡啶,并研究了它们对拓扑异构酶(topo)I和IIα的抑制特性以及在三种不同人类癌细胞系(HCT15、T47D和HeLa)中的抗增殖作用。在中心吡啶环的2-或6-位带有间位或对位酚的化合物22-30显示出显著的topo I和topo IIα双重抑制活性,对所有测试的人类癌细胞系均具有较强的抗增殖活性。然而,在中心吡啶环的2-或6-位带有邻位酚的化合物13-21未显示出显著的topo I和topo IIα抑制活性,但对所有测试的人类癌细胞系表现出中等的抗增殖活性。在T47D癌细胞系中,化合物23表现出最高的抗增殖效力,分别比依托泊苷和喜树碱高348.5倍和105倍。构效关系研究表明,中心吡啶的2-和6-苯环上羟基的对位以及4-苯环对位的氯原子表现出最显著的topo I和topo IIα抑制作用,这可能表明在4-吡啶苯环上引入氯原子作为topo I和topo IIα的双重抑制剂具有重要作用。选择在T47D细胞系中表现出最强的topo I和topo IIα双重抑制以及强抗增殖活性的化合物30进行进一步的作用机制研究,结果表明化合物30作为一种有效的DNA非嵌入性催化topo I和IIα双重抑制剂发挥作用。